Advancing personalized medicine is increasingly becoming the goal of many drug manufacturers and would be an obvious boon for both clinicians and patients. Immunohistochemistry (IHC)-based companion and complementary diagnostics that can help identify the right patient for the right drug are playing a major role in this trend. While a single-biomarker diagnostic test is clinically appealing due to its simplicity and low cost, the additional information that the right multi-biomarker test could offer is luring many developers to pursue multiplex strategies.
In this webinar, our expert panel will discuss:
- An overview of the multiplex technologies under consideration as potential diagnostic tools
- The pros and cons of singleplex IHC versus multibiomarker panels for patients, clinicians, cost centers, and regulators
- The hurdles faced by new companion diagnostics chemistries and what the regulatory pathway for their application might look like.
The panel will also answer questions from the live, online audience.
This webinar will last for approximately 60 minutes
You can also view Part 1 of this series.